Cargando…
Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer
One of the objectives of precision oncology is to identify patient’s responsiveness to a given treatment and prevent potential overtreatments through molecular profiling. Predictive gene expression biomarkers are a promising and practical means to this purpose. The overall response rate of paclitaxe...
Autores principales: | Feng, Xiaowen, Wang, Edwin, Cui, Qinghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405635/ https://www.ncbi.nlm.nih.gov/pubmed/30881385 http://dx.doi.org/10.3389/fgene.2019.00156 |
Ejemplares similares
-
A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer
por: Li, Na, et al.
Publicado: (2020) -
A machine learning-based approach to ERα bioactivity and drug ADMET prediction
por: An, Tianbo, et al.
Publicado: (2023) -
An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019) -
Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer
por: Su, Peng, et al.
Publicado: (2014) -
An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
por: Zhou, Xin, et al.
Publicado: (2014)